At a glance
- Originator Tanabe Seiyaku
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics
- Mechanism of Action 5-lipoxygenase inhibitors; Leukotriene receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 23 Jul 1998 No-Development-Reported for Inflammation in Japan (Unknown route)
- 08 May 1995 New profile
- 08 May 1995 Preclinical development for Inflammation in Japan (Unknown route)